ASCO GI Conference Coverage
Filter News By:

Featured Conference News

2021 GI Cancers Symposium: Preop Therapy Does Not Raise Surgical Risks in Thoracic Esophageal Cancer

January 16 2021 - Adding docetaxel or radiotherapy to cisplatin plus 5-fluorouracil as preoperative therapy does not appear to increase the risk of perioperative complications or mortality in patients with locally advanced, potentially resectable thoracic esophageal cancer, according to findings reported at the American Society of Clinical Oncology’s 2021 Gastrointestinal Cancers Symposium.

2021 GI Cancers Symposium: Pembrolizumab Combo is Safe in Rectal Cancer, Fails to Improve NAR Score

January 16 2021 - A Phase 2 trial demonstrated the safety of adding pembrolizumab to neoadjuvant chemoradiation to treat locally advanced rectal cancer (LARC). However, it failed to meet a primary endpoint of improving the neoadjuvant rectal (NAR) score, which combines pathologic nodal status with tumor downstaging.

2021 GI Cancers Symposium: Bemarituzumab Improves Gastric Cancer Survival, Response Rates

January 15 2021 - Adding bemarituzumab to modified FOLFOX (mFOLFOX) chemotherapy significantly improves survival and response rates for patients with advanced gastric cancer. The approach was associated with an increase in corneal adverse events and stomatitis.

Featured News
View all
More News
(ASCO Daily News) Jan 16, 2021 - Patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant therapy with modified FOLFIRINOX (mFOLFIRINOX) had an 18-month overall survival (OS) rate of 66.4% in a...
(ASCO Daily News) Jan 15, 2021 - Updated data on the JACCRO GC-07 trial presented during the 2021 Gastrointestinal Cancers Symposium based on a median follow-up of 42.5 months not only confirmed the RFS results previously seen but...
(ASCO Daily News) Jan 15, 2021 - Findings from the observational DELIVER trial sponsored by the Japan Clinical Cancer Research Organization showed that patients with advanced gastric cancer who responded to nivolumab treatment had a more...
(Yahoo! Finance) Jan 15, 2021 - Five Prime Therapeutics today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced...
(OBR) Jan 15, 2021 - Adding bemarituzumab to modified FOLFOX (mFOLFOX) chemotherapy significantly improves survival and response rates for patients with advanced gastric cancer. The approach was associated with an increase in corneal...
(Morningstar) Jan 15, 2021 - Puma Biotechnology, Inc. announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastrointestinal Cancers Symposium hosted by the American...
(Fight Colorectal Cancer) Jan 14, 2021 - Fight CRC’s research, titled Understanding the impact of COVID-19 on the colorectal cancer community: Barriers and Opportunities for Care, will be presented at the 2021 Gastrointestinal Cancer...
(Yahoo! Finance) Jan 15, 2021 - Zymeworks Inc. today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma...
(Morningstar) Jan 15, 2021 - AVEO Oncology today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor...
(Morningstar) Jan 15, 2021 - NantKwest and ImmunityBio’s QUILT 88 trial shows novel combination immunotherapy, which includes aldoxorubicin, has more than doubled historic median survival rates in patients.

OBR Tweets

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S